Septerna, Inc. $SEPN Shares Newly Purchased by Profund Advisors LLC

Key Points

• Profund Advisors acquired 38,262 Septerna shares worth approximately $1.5 million, while several other institutional investors also established sizable positions.
• Septerna reported a quarterly loss of $0.29 per share, beating estimates of $0.43, and generated $26.75 million in revenue versus expectations of $19.22 million.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of $52.44, despite recent insider selling and the stock’s 1.8% decline.

Profund Advisors LLC acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 38,262 shares of the company's stock, valued at approximately $1,497,000. Profund Advisors LLC owned approximately 0.08% of Septerna as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in SEPN. TRV GP V LLC acquired a new stake in shares of Septerna during the 2nd quarter worth about $208,160,143. TRV GP VI LLC purchased a new position in Septerna in the second quarter valued at approximately $141,048,460. BlackRock Inc. acquired a new stake in Septerna during the second quarter worth approximately $64,706,000. Jupiter Topco LLC acquired a new stake in Septerna during the second quarter worth approximately $43,723,000. Finally, Primecap Management Co. CA acquired a new stake in Septerna during the second quarter worth approximately $39,096,000.

Insiders Place Their Bets

In related news, SVP Daniel D. Long sold 3,333 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president owned 96,412 shares in the company, valued at $3,647,265.96. This represents a 3.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the sale, the chief operating officer owned 174,209 shares of the company's stock, valued at approximately $7,665,196. This represents a 12.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 32,333 shares of company stock worth $1,375,727 over the last ninety days. Corporate insiders own 5.80% of the company's stock.

Septerna Stock Down 1.8%

SEPN opened at $43.20 on Tuesday. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of -80.00 and a beta of 2.29. Septerna, Inc. has a 52 week low of $17.55 and a 52 week high of $51.10. The business's 50 day moving average is $39.02 and its two-hundred day moving average is $32.19.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analysts' expectations of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. Equities analysts expect that Septerna, Inc. will post -1.41 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Septerna in a research report on Thursday, October 15th. JPMorgan Chase & Co. increased their target price on shares of Septerna from $38.00 to $48.00 and gave the company an "overweight" rating in a research report on Wednesday, August 19th. JonesTrading lifted their price target on shares of Septerna from $43.00 to $62.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. HC Wainwright boosted their price target on shares of Septerna from $40.00 to $60.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $49.00 price target on shares of Septerna in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $52.44.

Septerna Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company's research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.